Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia - Wikidata - wikimedia - TriplyDB

Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia

Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia

http://www.wikidata.org/entity/Q33597526

about

Therapy-related acute promyelocytic leukemia Therapy-related myeloid neoplasms: pathobiology and clinical characteristics Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy.Therapy-related acute promyelocytic leukemia: a systematic review.Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.Global characteristics of childhood acute promyelocytic leukemia.Molecular pathogenesis of secondary acute promyelocytic leukemia Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era Yeast Assay Highlights the Intrinsic Genomic Instability of Human PML Intron 6 over Intron 3 and the Role of Replication Fork Proteins Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated?The cellular etiology of chromosome translocations.Topoisomerase II and leukemia.Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents.DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.Topoisomerase-mediated chromosomal break repair: an emerging player in many games.Nanocarriers for cancer-targeted drug delivery.Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database.All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'.Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients.Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.

P2860

Q24629042-5939B623-DC81-4042-B069-6AA79C8C7CCD Q28386366-E606891B-CBF2-4C55-B992-68B0284E79FA Q34227027-3985B9BB-D132-4060-8C53-2B4C65FEAC9B Q34351253-59276FE3-8C2F-404E-8568-E86188BFF8DC Q34870833-BE391734-7E39-40CE-915F-161322C3037D Q35231673-FBB89B91-73B4-44B0-B562-5686DEF219DE Q35560260-3F3E48F9-CF47-4297-ABEC-3815DC8C6A29 Q35640734-95FD9FA6-E21B-4C37-AD3C-9F3A85488A95 Q35656575-97A77764-CF60-4EA3-AA70-CA4C1D60E37A Q36714359-10CA6DFC-AB04-46EB-980C-3382A67D9DFE Q36944962-5ABE4357-8E83-4D11-A294-75008DB3FE68 Q37652882-F98CAC83-5324-41AD-A8EF-50E12983E682 Q38029323-18041AC8-DE8D-42A5-8923-E3E14C5731AF Q38052129-9223690B-7BB3-4407-B3E8-2409837E71D5 Q38360744-94E91A17-93E8-4C02-B5F1-3CC1BA7D4B12 Q38523681-02BCEAE4-33F6-459D-A009-75F210DF14AE Q38891536-7061AC2D-02CC-4EC0-BFFC-62343F88A5C2 Q41662169-4238B455-3FC1-4C61-B4C2-1974AF99D574 Q43084094-898BCBF3-AC70-4BFD-B1A3-5A78836832C7 Q43115838-C96879B9-4BCF-41B7-BBF1-EF9D78BE7103 Q49977881-EE08CD65-2BC6-4968-93BB-D2F6F12DBFEF

P2860

Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia

http://www.wikidata.org/entity/Q33597526

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Evidence for direct involvemen ...... d acute promyelocytic leukemia

@ast

Evidence for direct involvemen ...... d acute promyelocytic leukemia

@en

type

label

Evidence for direct involvemen ...... d acute promyelocytic leukemia

@ast

Evidence for direct involvemen ...... d acute promyelocytic leukemia

@en

prefLabel

Evidence for direct involvemen ...... d acute promyelocytic leukemia

@ast

Evidence for direct involvemen ...... d acute promyelocytic leukemia

@en

P1433

Q33597526-69262891-A2F5-4561-BBAB-C7720FF0708C

P1476

Q33597526-54C0786E-4B93-45AC-8C2D-2EC05254B8E1

P2093

Q33597526-0B28B7B6-1655-4319-9B8D-643E36E35E69

Q33597526-17137CA1-C74B-44E1-95BE-678699DC12B6

Q33597526-201157C3-3EF4-4A5F-8416-A7F8B14DB96F

Q33597526-21193AC4-0183-4874-B8EC-7DA3A4F4B52D

Q33597526-3AB80C13-0272-453D-BAE2-3E5CD7325CE2

Q33597526-46CCCB0E-AA61-4788-A5FD-E5D5C9C28E0C

Q33597526-7877EB9C-EF23-41F8-A165-2746A9DB1932

Q33597526-8419E837-F4A9-4191-8971-8FCA10302A17

Q33597526-89EE82E5-5700-40D8-ACA1-32301CFFCF2E

Q33597526-9881DFBC-0718-4983-ABE6-44192EB8BEE7

P2860

Q33597526-07F3FAF9-96FF-4EDE-A0D5-A3A7A094BCEF

Q33597526-126F35E5-FDE4-4FFA-97D1-0A26A640AF14

Q33597526-1A8AB61A-6FD8-4792-83C2-40D9E903068E

Q33597526-1E232BFF-50C5-4BAF-A5A6-111273D94A20

Q33597526-30E56B46-92EB-46C5-B2EB-6B888B3A0461

Q33597526-37F02A74-9830-4981-AAAE-CE0039F047DE

Q33597526-55ACDF91-DA29-45BB-AB99-86E6B80356AC

Q33597526-5FB2BC29-4308-479B-8355-90C690B32812

Q33597526-6E38BE42-C1F2-4277-9EBE-03A6FAD746B4

Q33597526-89DC3CCF-5891-4426-A4C4-97BCD23DA01E

P304

Q33597526-D1448B6A-7157-415F-AE05-C62217EF0212

P31

Q33597526-2B074797-97E2-4BCF-B62E-339018602AE3

P356

Q33597526-AC857116-1513-4B6C-B6BF-6AAD90434FE6

P407

Q33597526-6BB4F9F0-1909-4085-930E-72E97A2BEBFD

P433

Q33597526-2AAA0294-5B36-4C80-A444-A266E49B3AAB

P478

Q33597526-5984D01B-AEFA-44E5-87D9-7803461C9D71

P50

Q33597526-8BDF4A04-EE3F-4F9E-A291-786FF20D31FF

Q33597526-93FDDD6A-84D5-44A6-9C0C-9E2798A6E635

P577

Q33597526-9F87AB98-EB4A-47FF-A987-B6093A1C2824

P5875

Q33597526-72F82FDF-D135-404A-A987-8CBCA0ACB250

P698

Q33597526-781F9709-1FEA-4D79-A1F8-64E472E938A8

P921

Q33597526-A86C7A90-A837-4834-8568-1B63EA074701

P932

Q33597526-80262E60-7BED-4821-87FD-18F44410DC0D

P356

BLOOD-2009-07-235051

P1433

P1476

Evidence for direct involvemen ...... d acute promyelocytic leukemia

@en

P2093

Andrew Peniket

http://www.w3.org/2001/XMLSchema#string

Ashley N Mays

http://www.w3.org/2001/XMLSchema#string

Carolyn A Felix

http://www.w3.org/2001/XMLSchema#string

Cherry Chang

http://www.w3.org/2001/XMLSchema#string

Christine Hoyle

http://www.w3.org/2001/XMLSchema#string

David Grimwade

http://www.w3.org/2001/XMLSchema#string

Ellen Solomon

http://www.w3.org/2001/XMLSchema#string

Jo Ann W Byl

http://www.w3.org/2001/XMLSchema#string

Joseph L Wiemels

http://www.w3.org/2001/XMLSchema#string

Kandeepan Saravanamuttu

http://www.w3.org/2001/XMLSchema#string

P2860

Chromosome translocations and covert leukemic clones are generated during normal fetal development

Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis

Mechanisms of therapy-related carcinogenesis.

Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions.

Topoisomerase II and the etiology of chromosomal translocations.

Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia.

DNA topoisomerase II, genotoxicity, and cancer

The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing

Nucleolytic cleavage of the mixed lineage leukemia breakpoint cluster region during apoptosis.

DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis

P304

326-330

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-07-235051

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Lo-Coco

P577

2009-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38062715

http://www.w3.org/2001/XMLSchema#string

P698

19884644

http://www.w3.org/2001/XMLSchema#string

P921

P932

2808156

http://www.w3.org/2001/XMLSchema#string